Bioeq AG is a Swiss biopharmaceutical joint venture backed by the leading biosimilar developers Polpharma Biologics Group and Formycon AG and is based in Zug. We license, develop and commercialise a biosimilar, which is a successor product of Lucentis® (ranibizumab), a successful branded biopharmaceutical. 

We are a young and dynamic company, supported by an international network of experts. Bioeq AG out-licenses its products to established international pharmaceutical companies who ensure local distribution in each territory.

Pharmaceutical

Life Sciences

Biotechnology

Bioeq AG

Bioeq AG's headquarters in Zug, Switzerland

Bioeq AG

Org chart

Teams

Offices

Similar companies